Cover Image
市場調查報告書

POC/迅速診斷的全球市場的預測 (∼2022年):葡萄糖、脂質、HbA1c、HCV、HIV、流感、尿液檢查、血液學的檢驗、癌症、妊娠、PT/INR

Point-of-Care/Rapid Diagnostics Market by Testing (Glucose, Lipids, HbA1c, HCV, HIV, Influenza, Urinalysis, Hematology, Cancer, Pregnancy, PT/INR), Platform (Lateral Flow, Immunoassay), Mode (Prescription, OTC), End-User - Global Forecast to 2022

出版商 MarketsandMarkets 商品編碼 298728
出版日期 內容資訊 英文 228 Pages
訂單完成後即時交付
價格
Back to Top
POC/迅速診斷的全球市場的預測 (∼2022年):葡萄糖、脂質、HbA1c、HCV、HIV、流感、尿液檢查、血液學的檢驗、癌症、妊娠、PT/INR Point-of-Care/Rapid Diagnostics Market by Testing (Glucose, Lipids, HbA1c, HCV, HIV, Influenza, Urinalysis, Hematology, Cancer, Pregnancy, PT/INR), Platform (Lateral Flow, Immunoassay), Mode (Prescription, OTC), End-User - Global Forecast to 2022
出版日期: 2018年02月19日 內容資訊: 英文 228 Pages
簡介

全球POC/迅速診斷的市場在預測期間內預計以10.0%的年複合成長率發展,從2017年的237億1000萬美元,成長到2022年的381億3000萬美元的規模。新興各國的感染疾病的高盛行率,對象疾病的罹患率上升,轉向居家照護的趨勢擴大等要素促進該市場的成長。

本報告提供全球POC/迅速診斷檢驗的市場調查,市場定義和概要,市場成長的各種影響因素及市場機會分析,各產品區分、平台、處方方式、終端用戶、地區/主要國家趨勢與市場規模的變化與預測,競爭環境,主要企業簡介等彙整。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

第5章 POC/迅速診斷的全球市場:概要

  • 簡介
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 課題
    • 新的用途

第6章 市場分析、預測:各產品

  • 簡介
  • 血糖監測系統產品
    • 儀表
    • 採血針、穿刺器
  • 心血管代謝檢驗產品
    • 心臟標記
    • 血氣/電解液檢驗
    • HBA1C檢驗
  • 傳染病檢查產品
    • 流感檢驗產品
    • HIV檢驗產品
    • C型肝炎檢驗產品
    • 性感染疾病 (STD) 檢驗產品
    • 醫療相關感染 (HAI) 檢驗產品
    • 呼吸系統感染檢驗產品
    • 熱帶病檢驗產品
    • 其他
  • 血液凝固檢查產品
    • 凝血酵素原時間 (PT/INR) 檢驗
    • 活性凝固時間 (ACT/APTT) 檢驗
  • 妊娠、妊娠能力檢驗產品
    • 妊娠檢驗
    • 妊娠能力檢驗
  • 腫瘤/癌症標記
  • 尿液檢查檢驗產品
  • 膽固醇檢驗產品
  • 血液學的檢驗產品
  • 藥物濫用檢測產品
  • 糞便潛血反應檢驗產品
  • 其他

第7章 市場分析、預測:各平台

  • 簡介
  • 側流化驗 (免疫層析檢驗)
  • 沾醬棒
  • 微射流
  • 分子診斷
  • 免疫檢測

第8章 市場分析、預測:各處方模式

  • 簡介
  • 處方為基礎的檢驗
  • OTC檢驗

第9章 市場分析、預測:各終端用戶

  • 簡介
  • 專業診斷中心
    • 門診病人醫療設施
    • 醫院/急救中心
  • 居家照護
  • 研究實驗室
  • 其他

第10章 地區分析

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 其他
  • 其他地區
    • 南美
    • 中東、非洲

第11章 競爭環境

  • 概要
  • 市場佔有率分析
  • 競爭模式、趨勢
    • 產品的投入
    • 協定、聯盟、合作
    • 產品的認證
    • 收購

第12章 企業簡介

  • ABBOTT LABORATORIES
  • ACCUBIOTECH
  • BECTON, DICKINSON, AND COMPANY (BD)
  • CHEMBIO DIAGNOSTICS
  • DANAHER CORPORATION
  • EKF DIAGNOSTICS
  • INSTRUMENTATION LABORATORY
  • JOHNSON & JOHNSON
  • NOVA BIOMEDICAL
  • PTS DIAGNOSTICS
  • QUIDEL
  • ROCHE DIAGNOSTICS
  • SEKISUI DIAGNOSTICS
  • SIEMENS
  • TRINITY BIOTECH

第13章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MD 2702

"The point-of-care diagnostics market projected to grow at a CAGR of 10.0%."

The global point-of-care diagnostics market is projected to reach USD 38.13 billion by 2022 from USD 23.71 billion in 2017, at a CAGR of 10.0%. High prevalence of infectious diseases in developing countries, increasing incidence of target diseases, and increasing inclination toward home healthcare across the globe are the factors expected to drive the market during the study period. However, the lack of alignment with definitive central lab methods, certain disadvantages of POC testing over central lab methods, and the reluctance among physicians to change existing diagnostic practices are the key factors that are limiting the growth of this market.

"The glucose monitoring products segment is expected to command the largest share of the POC diagnostics market in 2017."

On the basis of product, the glucose monitoring products segment is expected to command the largest share of the global POC diagnostics market in 2017. The large share of this segment can be attributed to the growing incidence and prevalence of diabetes across the globe and rising preference for home glucose testing.

"The molecular diagnostics segment is expected to be the fastest-growing segment during the forecast period."

On the basis of platform, the market is segmented into lateral flow assays, dipsticks, microfluidics, molecular diagnostics, and immunoassays. The molecular diagnostics segment is expected to be the fastest-growing segment during the forecast period. Growing advancements in technology and increasing initiatives of market players for developing POC molecular diagnostic products is propelling the demand for molecular diagnostics.

"Asia Pacific is expected grow at the highest CAGR during the forecast period."

Geographically, the point-of-care diagnostics market is segmented into North America, Europe, Asia Pacific, and RoW. Asia Pacific is expected to register the highest growth rate during the forecast period due to the growing initiatives by market players, increasing patient population base, and rising number of partnerships and joint ventures in this region.

Breakdown of supply-side primary interviews:

  • By Company Type - Tier 1 - 35%, Tier 2 - 45% and Tier 3 - 20%
  • By Designation - - C level - 15%, Director level - 30%, Others - 55%
  • By Region - North America - 45%, Europe - 20%, APAC - 30%, RoW - 5%

The major players of the point-of-care diagnostics market are Abbott (US), Roche (Switzerland), Siemens (Germany), Danaher (US), Becton, Dickinson, and Company (US), Johnson & Johnson (US), Instrumentation Laboratory (US), PTS Diagnostics (US), Quidel (US), Chembio (US), Sekisui Diagnostics (US), Nova (US), EKF Diagnostics (UK), AccuBioTech (China), and Trinity Biotech (US).

Research Coverage:

This report studies the point-of-care diagnostics market based on product, platform, mode, end user, and region. The report also studies factors affecting market growth, it analyzes opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends. The report forecasts the revenue of market segments with respect to the four key regions and respective countries.

Reasons to Buy the Report:

From an insights perspective, this research report has focused on various levels of analysis- market ranking analysis of top players, and company profiles, which together comprise and discuss basic views on the competitive landscape, emerging segments of the point-of-care diagnostics market, and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, will help firms garner greater market shares.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
  • 1.4. MARKETS COVERED
    • 1.4.1. YEARS CONSIDERED FOR THE STUDY
  • 1.5. CURRENCY
  • 1.6. LIMITATIONS
  • 1.7. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH DATA
    • 2.1.1. SECONDARY DATA
      • 2.1.1.1. Secondary sources
    • 2.1.2. PRIMARY DATA
      • 2.1.2.1. Primary sources
      • 2.1.2.2. Key Industry Insights
    • 2.1.3. MARKET SIZE ESTIMATION METHODOLOGY
      • 2.1.3.1. BOTTOM-UP APPROACH
      • 2.1.3.2. TOP-DOWN APPROACH
    • 2.1.4. RESEARCH DESIGN
    • 2.1.5. MARKET DATA VALIDATION AND TRIANGULATION
    • 2.1.6. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION

4. PREMIUM INSIGHTS

  • 4.1. POC DIAGNOSTICS: MARKET OVERVIEW
  • 4.2. POC DIAGNOSTICS MARKET, BY PLATFORM
  • 4.3. GEOGRAPHIC ANALYSIS: POC DIAGNOSTICS MARKET, BY END USER AND REGION
  • 4.4. POC DIAGNOSTICS MARKET, BY PRODUCT
  • 4.5. POC DIAGNOSTICS MARKET, BY PRESCRIPTION MODE
  • 4.6. GEOGRAPHIC SNAPSHOT OF THE POC DIAGNOSTICS MARKET

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. High prevalence of infectious diseases in developing countries
      • 5.2.1.2. Increasing incidence of target diseases
      • 5.2.1.3. Rising usage of home-based POC devices
      • 5.2.1.4. Growing government support
      • 5.2.1.5. Technological advancements and new product launches
      • 5.2.1.6. Growing number of regulatory approvals for novel immunoassay techniques
      • 5.2.1.7. Shortage of skilled laboratory technicians
      • 5.2.1.8. Rising number of CLIA-waived POC tests
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. Product recalls: Hampering user confidence
      • 5.2.2.2. Pricing pressure owing to reimbursement cuts and budget constraints
      • 5.2.2.3. Stringent and time-consuming regulatory policies are significantly increasing gestation period for product launches
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Growth opportunities in emerging markets
      • 5.2.3.2. Healthcare decentralization -Converting lab tests to POC tests
      • 5.2.3.3. Increasing number of conferences and events
      • 5.2.3.4. POC tests with multiplexing capabilities
    • 5.2.4. CHALLENGES
      • 5.2.4.1. Lack of alignment with definitive central lab methods
        • 5.2.4.1.1. Disadvantages of POC testing over central lab methods
      • 5.2.4.2. Inadequate knowledge about the use of POC devices in professional settings
      • 5.2.4.3. Reluctance towards changing existing diagnostic practices
      • 5.2.4.4. High cost of devices
    • 5.2.5. EMERGING APPLICATIONS OF POINT-OF-CARE TESTING
      • 5.2.5.1. Sepsis biomarkers
      • 5.2.5.2. Stroke markers
      • 5.2.5.3. Thyroid testing
      • 5.2.5.4. DNA testing
      • 5.2.5.5. Endocrine testing

6. POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT

  • 6.1. INTRODUCTION
  • 6.2. GLUCOSE MONITORING PRODUCTS
    • 6.2.1. STRIPS
    • 6.2.2. METERS
    • 6.2.3. LANCETS & LANCING DEVICES
  • 6.3. CARDIOMETABOLIC TESTING PRODUCTS
    • 6.3.1. CARDIAC MARKER TESTING PRODUCTS
    • 6.3.2. BLOOD GAS/ELECTROLYTES TESTING PRODUCTS
    • 6.3.3. HBA1C TESTING PRODUCTS
  • 6.4. INFECTIOUS DISEASE TESTING PRODUCTS
    • 6.4.1. INFLUENZA TESTING PRODUCTS
    • 6.4.2. HIV TESTING PRODUCTS
    • 6.4.3. HEPATITIS C TESTING PRODUCTS
    • 6.4.4. SEXUALLY TRANSMITTED DISEASE (STD) TESTING PRODUCTS
    • 6.4.5. HEALTHCARE-ASSOCIATED INFECTION (HAI) TESTING PRODUCTS
    • 6.4.6. RESPIRATORY INFECTION TESTING PRODUCTS
    • 6.4.7. TROPICAL DISEASE TESTING PRODUCTS
    • 6.4.8. OTHER INFECTIOUS DISEASE TESTING PRODUCTS
  • 6.5. COAGULATION TESTING PRODUCTS
    • 6.5.1. PT/INR TESTING PRODUCTS
    • 6.5.2. ACTIVATED CLOTTING TIME (ACT/APTT) TESTING PRODUCTS
  • 6.6. PREGNANCY AND FERTILITY TESTING PRODUCTS
    • 6.6.1. PREGNANCY TESTING PRODUCTS
    • 6.6.2. FERTILITY TESTING PRODUCTS
  • 6.7. TUMOR/CANCER MARKER TESTING PRODUCTS
  • 6.8. URINALYSIS TESTING PRODUCTS
  • 6.9. CHOLESTEROL TESTING PRODUCTS
  • 6.10. HEMATOLOGY TESTING PRODUCTS
  • 6.11. DRUGS-OF-ABUSE TESTING PRODUCTS
  • 6.12. FECAL OCCULT TESTING PRODUCTS
  • 6.13. OTHER POC PRODUCTS

7. POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM

  • 7.1. INTRODUCTION
  • 7.2. LATERAL FLOW ASSAYS (IMMUNOCHROMATOGRAPHY TESTS)
  • 7.3. DIPSTICKS
  • 7.4. MICROFLUIDICS
  • 7.5. MOLECULAR DIAGNOSTICS
  • 7.6. IMMUNOASSAYS

8. POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE

  • 8.1. INTRODUCTION
  • 8.2. PRESCRIPTION-BASED TESTING
  • 8.3. OTC TESTING

9. POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER

  • 9.1. INTRODUCTION
  • 9.2. PROFESSIONAL DIAGNOSTIC CENTERS
    • 9.2.1. OUTPATIENT HEALTHCARE & AMBULATORY CARE SETTINGS
    • 9.2.2. HOSPITALS/CRITICAL CARE CENTERS
  • 9.3. HOME CARE
  • 9.4. RESEARCH LABORATORIES
  • 9.5. OTHER END USERS

10. POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. US
    • 10.2.2. CANADA
  • 10.3. EUROPE
    • 10.3.1. GERMANY
    • 10.3.2. FRANCE
    • 10.3.3. UK
    • 10.3.4. REST OF EUROPE (ROE)
  • 10.4. ASIA PACIFIC
    • 10.4.1. JAPAN
    • 10.4.2. CHINA
    • 10.4.3. INDIA
    • 10.4.4. REST OF ASIA PACIFIC
  • 10.5. REST OF THE WORLD (ROW)
    • 10.5.1. LATIN AMERICA
    • 10.5.2. MIDDLE EAST & AFRICA

11. COMPETITIVE LANDSCAPE

  • 11.1. OVERVIEW
  • 11.2. MARKET SHARE ANALYSIS, 2016
  • 11.3. COMPETITIVE SCENARIO AND TRENDS
    • 11.3.1. PRODUCT LAUNCHES
    • 11.3.2. AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
    • 11.3.3. PRODUCT APPROVALS
    • 11.3.4. ACQUISITIONS

12. COMPANY PROFILES (Business Overview, Products Offered, Recent Developments, Mnm View)*

  • 12.1. ABBOTT LABORATORIES
  • 12.2. ACCUBIOTECH
  • 12.3. BECTON, DICKINSON, AND COMPANY (BD)
  • 12.4. CHEMBIO DIAGNOSTICS
  • 12.5. DANAHER CORPORATION
  • 12.6. EKF DIAGNOSTICS
  • 12.7. INSTRUMENTATION LABORATORY (A WERFEN COMPANY)
  • 12.8. JOHNSON & JOHNSON
  • 12.9. NOVA BIOMEDICAL
  • 12.10. PTS DIAGNOSTICS (A PART OF SINOCARE INC.)
  • 12.11. QUIDEL
  • 12.12. ROCHE DIAGNOSTICS (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD.)
  • 12.13. SEKISUI DIAGNOSTICS
  • 12.14. SIEMENS
  • 12.15. TRINITY BIOTECH

*Business Overview, Products Offered, Recent Developments, Mnm View might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. DISCUSSION GUIDE
  • 13.2. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.4. AVAILABLE CUSTOMIZATIONS
  • 13.5. RELATED REPORTS
  • 13.6. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 2: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 3: GLUCOSE MONITORING METERS MARKET, BY REGION, 2015-2022 (UNITS)
  • TABLE 4: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 5: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC TESTING PRODUCTS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 6: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC TESTING PRODUCTS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 7: CARDIAC MARKER TESTING PRODUCTS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 8: CARDIAC MARKER TESTING PRODUCTS MARKET, BY REGION, 2015-2022 (UNITS)
  • TABLE 9: BLOOD GAS/ELECTROLYTES TESTING PRODUCTS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 10: BLOOD GAS/ELECTROLYTES TESTING ANALYZERS MARKET, BY REGION, 2015-2022 (UNITS)
  • TABLE 11: HBA1C TESTING PRODUCTS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 12: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 13: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 14: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 15: INFLUENZA TESTING ANALYZERS MARKET, BY REGION, 2015-2022 (UNITS)
  • TABLE 16: HIV TESTING PRODUCTS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 17: HIV TESTING ANALYZERS MARKET, BY REGION, 2015-2022 (UNITS)
  • TABLE 18: HEPATITIS C TESTING PRODUCTS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 19: HEPATITIS C TESTING ANALYZERS MARKET, BY REGION, 2015-2022 (UNITS)
  • TABLE 20: STD TESTING PRODUCTS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 21: HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 22: RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 23: TROPICAL DISEASE TESTING PRODUCTS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 24: OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 25: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION TESTING PRODUCTS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 26: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION TESTING PRODUCTS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 27: COAGULATION TESTING ANALYZERS MARKET, BY REGION, 2015-2022 (UNITS)
  • TABLE 28: PT/INR TESTING PRODUCTS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 29: ACT/APTT TESTING PRODUCTS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 30: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 31: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 32: PREGNANCY TESTING PRODUCTS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 33: FERTILITY TESTING PRODUCTS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 34: POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 35: POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 36: URINALYSIS TESTING ANALYZERS MARKET, BY REGION, 2015-2022 (UNITS)
  • TABLE 37: POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 38: CHOLESTEROL TESTING ANALYZERS MARKET, BY REGION, 2015-2022 (UNITS)
  • TABLE 39: POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 40: HEMATOLOGY TESTING ANALYZERS MARKET, BY REGION, 2015-2022 (UNITS)
  • TABLE 41: POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 42: POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 43: POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 44: POC DIAGNOSTICS MARKET, BY PLATFORM, 2015-2022 (USD MILLION)
  • TABLE 45: LATERAL FLOW ASSAYS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 46: DIPSTICKS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 47: MICROFLUIDICS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 48: MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 49: IMMUNOASSAYS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 50: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2015-2022 (USD MILLION)
  • TABLE 51: PRESCRIPTION-BASED TESTING MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 52: OTC TESTING PRODUCTS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 53: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 54: POINT-OF-CARE DIAGNOSTICS MARKET FOR PROFESSIONAL DIAGNOSTIC CENTERS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 55: POINT-OF-CARE DIAGNOSTICS MARKET FOR PROFESSIONAL DIAGNOSTIC CENTERS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 56: POINT-OF-CARE DIAGNOSTICS MARKET FOR OUTPATIENT HEALTHCARE & AMBULATORY CARE SETTINGS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 57: POINT-OF-CARE DIAGNOSTICS MARKET FOR HOSPITALS/CRITICAL CARE CENTERS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 58: POINT-OF-CARE MARKET FOR HOME CARE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 59: POINT-OF-CARE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 60: POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 61: POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 62: NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 63: NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 64: NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2015-2022 (USD MILLION)
  • TABLE 65: NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2015-2022 (USD MILLION)
  • TABLE 66: NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 67: US: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 68: US: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2015-2022 (USD MILLION)
  • TABLE 69: US: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2015-2022 (USD MILLION)
  • TABLE 70: US: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 71: CANADA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 72: CANADA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2015-2022 (USD MILLION)
  • TABLE 73: CANADA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2015-2022 (USD MILLION)
  • TABLE 74: CANADA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 75: EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 76: EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 77: EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2015-2022 (USD MILLION)
  • TABLE 78: EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2015-2022 (USD MILLION)
  • TABLE 79: EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 80: GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 81: GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2015-2022 (USD MILLION)
  • TABLE 82: GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2015-2022 (USD MILLION)
  • TABLE 83: GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 84: FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 85: FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2015-2022 (USD MILLION)
  • TABLE 86: FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2015-2022 (USD MILLION)
  • TABLE 87: FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 88: UK: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 89: UK: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2015-2022 (USD MILLION)
  • TABLE 90: UK: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2015-2022 (USD MILLION)
  • TABLE 91: UK: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 92: ROE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 93: ROE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2015-2022 (USD MILLION)
  • TABLE 94: ROE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2015-2022 (USD MILLION)
  • TABLE 95: ROE: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 96: APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 97: APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 98: APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2015-2022 (USD MILLION)
  • TABLE 99: APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2015-2022 (USD MILLION)
  • TABLE 100: APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 101: JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 102: JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2015-2022 (USD MILLION)
  • TABLE 103: JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2015-2022 (USD MILLION)
  • TABLE 104: JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 105: CHINA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 106: CHINA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2015-2022 (USD MILLION)
  • TABLE 107: CHINA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2015-2022 (USD MILLION)
  • TABLE 108: CHINA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 109: INDIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 110: INDIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2015-2022 (USD MILLION)
  • TABLE 111: INDIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2015-2022 (USD MILLION)
  • TABLE 112: INDIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 113: ROAPAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 114: ROAPAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2015-2022 (USD MILLION)
  • TABLE 115: ROAPAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2015-2022 (USD MILLION)
  • TABLE 116: ROAPAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 117: ROW: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 118: ROW: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 119: ROW: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2015-2022 (USD MILLION)
  • TABLE 120: ROW: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2015-2022 (USD MILLION)
  • TABLE 121: ROW: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 122: LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 123: LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2015-2022 (USD MILLION)
  • TABLE 124: LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2015-2022 (USD MILLION)
  • TABLE 125: LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 126: MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 127: MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2015-2022 (USD MILLION)
  • TABLE 128: MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2015-2022 (USD MILLION)
  • TABLE 129: MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1: RESEARCH METHODOLOGY STEPS
  • FIGURE 2: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3: DATA TRIANGULATION
  • FIGURE 4: GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017 VS. 2022
  • FIGURE 5: GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2017 VS. 2022
  • FIGURE 6: GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2017 VS. 2022
  • FIGURE 7: GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2017 VS. 2022
  • FIGURE 8: GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION, 2017 (USD MILLION)
  • FIGURE 9: HIGH PREVALENCE OF INFECTIOUS DISEASES IS DRIVING THE ADOPTION OF POC DEVICES ACROSS THE GLOBE
  • FIGURE 10: LATERAL FLOW ASSAYS SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2022
  • FIGURE 11: PROFESSIONAL DIAGNOSTIC CENTERS SEGMENT TO DOMINATE THE GLOBAL POC DIAGNOSTICS END-USER MARKET IN 2017
  • FIGURE 12: GLUCOSE MONITORING SEGMENT TO DOMINATE THE POC DIAGNOSTICS PRODUCTS MARKET DURING THE FORECAST PERIOD
  • FIGURE 13: PRESCRIPTION-BASED TESTING PRODUCTS TO DOMINATE THE POC DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
  • FIGURE 14: NORTH AMERICA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 15: POC DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 16: ESTIMATED NUMBER OF DIABETIC PATIENTS, BY REGION, 2015 VS. 2040
  • FIGURE 17: THE INFECTIOUS DISEASE TESTING PRODUCTS SEGMENT IS PROJECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 18: MOLECULAR DIAGNOSTICS SEGMENT TO WITNESS HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 19: OTC TESTING SEGMENT TO WITNESS HIGHER GROWTH DURING THE FORECAST PERIOD
  • FIGURE 20: HOME CARE TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 21: POINT-OF-CARE DIAGNOSTICS MARKET: GROWTH FORECAST, BY REGION (2017-2022)
  • FIGURE 22: NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 23: EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 24: APAC: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 25: KEY DEVELOPMENTS BY LEADING MARKET PLAYERS IN THE MARKET, 2015-2017
  • FIGURE 26: POINT-OF-CARE DIAGNOSTICS MARKET SHARE, BY KEY PLAYERS, 2016
  • FIGURE 27: ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • FIGURE 28: BD: COMPANY SNAPSHOT
  • FIGURE 29: CHEMBIO DIAGNOSTICS: COMPANY SNAPSHOT
  • FIGURE 30: DANAHER CORPORATION: COMPANY SNAPSHOT
  • FIGURE 31: EKF DIAGNOSTICS: COMPANY SNAPSHOT
  • FIGURE 32: JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • FIGURE 33: QUIDEL: COMPANY SNAPSHOT
  • FIGURE 34: ROCHE DIAGNOSTICS: COMPANY SNAPSHOT
  • FIGURE 35: SIEMENS: COMPANY SNAPSHOT
  • FIGURE 36: TRINITY BIOTECH: COMPANY SNAPSHOT
Back to Top